Literature DB >> 30590198

Exploring the multicomponent synergy mechanism of Banxia Xiexin Decoction on irritable bowel syndrome by a systems pharmacology strategy.

Bangjie Li1, Junqian Rui2, Xuejian Ding3, Xinghao Yang4.   

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE: Banxia Xiexin Decoction (BXD) is a representative prescription to regulate spleen and stomach in "Treatise on Febrile Diseases", which has been proven effective for the clinical treatment of irritable bowel syndrome (IBS) in the past decades. However, the active principles and molecular mechanisms involved in BXD against IBS are vague yet. AIM OF THE STUDY: To unfold multicomponent synergy mechanism of BXD on irritable bowel syndrome, this work explored active principles, drug targets and crucial pathways using a systems pharmacology strategy.
MATERIALS AND METHODS: In this study, a systems pharmacology based strategy was applied by the procedures integrating compound database construction, ADME evaluation, target identification, functional annotation, pathway enrichment analysis, network analysis, and molecular docking verification. The 158 compounds from BXD were selected for the screening. The Compound-Target network (C-T) and the Target-Pathway network (T-P) were constructed. The bioinformatics and network topology were employed to systematically reveal multicomponent-target interactions of BXD. The affinity between important ingredients and the kernel targets was validated using molecular mechanics simulation.
RESULTS: The 35 potential important ingredients and the 16 associated kernel targets were identified. 27 crucial pathways, in which the kernel targets participated, could regulate the biological processes, such as synthesis of inflammatory mediators, smooth muscle relaxation and synaptic plasticity, closely related to pathological mechanism of IBS. The cross-talk interactions were revealed between TNF signaling pathway, Dopaminergic synapse and cGMP-PKG signaling pathway, which would exert the synergistic influences on the occurrence and treatment of the IBS. PTGS2, CALM, NOS2, SCN5A, and PRSS1 might become novel drug targets for IBS.
CONCLUSIONS: The study demonstrated that the synergy molecular mechanisms of BXD mainly involved three therapeutic modules including inhibiting inflammatory reaction, maintaining intestinal function and improving psychological regulation via the multicomponent-target interaction networks. It may also provide the promising drug targets and therapeutic agents for the development of new medicines.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Banxia Xiexin Decoction; Irritable bowel syndrome; Systems pharmacology

Mesh:

Substances:

Year:  2018        PMID: 30590198     DOI: 10.1016/j.jep.2018.12.033

Source DB:  PubMed          Journal:  J Ethnopharmacol        ISSN: 0378-8741            Impact factor:   4.360


  17 in total

1.  An Integrated Gut Microbiota and Network Pharmacology Study on Fuzi-Lizhong Pill for Treating Diarrhea-Predominant Irritable Bowel Syndrome.

Authors:  Zhang Zhen; Lin Xia; Huang You; Zhou Jingwei; Yang Shasha; Wei Xinyi; Lai Wenjing; Zhang Xin; Fu Chaomei
Journal:  Front Pharmacol       Date:  2021-11-30       Impact factor: 5.810

2.  Integrated Network Pharmacology and Metabolomics Analysis to Reveal the Potential Mechanism of Siwu Paste on Aplastic Anemia Induced by Chemotherapy Drugs.

Authors:  Dan He; Wan Dan; Qing Du; Bing-Bing Shen; Lin Chen; Liang-Zi Fang; Jian-Jun Kuang; Chun-Yu Tang; Ping Cai; Rong Yu; Shui-Han Zhang; Jian-Hua Huang
Journal:  Drug Des Devel Ther       Date:  2022-04-28       Impact factor: 4.319

3.  Network Pharmacological Study on Mechanism of the Therapeutic Effect of Modified Duhuo Jisheng Decoction in Osteoporosis.

Authors:  Xudong Huang; Zhou Zhou; Yingyi Zheng; Guoshuai Fan; Baihe Ni; Meichen Liu; Minghua Zhao; Lingfeng Zeng; Weiguo Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-31       Impact factor: 5.555

4.  Exploring Pharmacological Mechanisms of Xiang Ju Tablets in the Treatment of Allergic Rhinitis via a Network Pharmacology Approach.

Authors:  Kun Xia Hu; Xi Duan; Li Zhu Han; Hong Ye Ju; Bin Wang; Zhi Shu Tang; Xiao Song
Journal:  Evid Based Complement Alternat Med       Date:  2019-09-12       Impact factor: 2.629

5.  Tong-Xie-Yao-Fang improves intestinal permeability in diarrhoea-predominant irritable bowel syndrome rats by inhibiting the NF-κB and notch signalling pathways.

Authors:  Qiuke Hou; Yongquan Huang; Zhaoyang Zhu; Liu Liao; Xinlin Chen; Quanbin Han; Fengbin Liu
Journal:  BMC Complement Altern Med       Date:  2019-11-27       Impact factor: 3.659

6.  A Systems Pharmacology Approach for Identifying the Multiple Mechanisms of Action for the Rougui-Fuzi Herb Pair in the Treatment of Cardiocerebral Vascular Diseases.

Authors:  Chun Li; Xia Du; Yang Liu; Qi-Qi Liu; Wen Bing Zhi; Chun Liu Wang; Jie Zhou; Ye Li; Hong Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2020-01-08       Impact factor: 2.629

7.  A Network Pharmacology-Based Strategy For Predicting Active Ingredients And Potential Targets Of LiuWei DiHuang Pill In Treating Type 2 Diabetes Mellitus.

Authors:  Shui-Han Zhang; Yu-Hui Qin; Dan He; Jian-Hua Huang; Zhe-Yu Zhang; Qing Du; Wei-Jun Peng; Rong Yu; Si-Fang Zhang
Journal:  Drug Des Devel Ther       Date:  2019-11-28       Impact factor: 4.162

8.  In Silico and In Vivo Studies on the Mechanisms of Chinese Medicine Formula (Gegen Qinlian Decoction) in the Treatment of Ulcerative Colitis.

Authors:  Xiaolu Liu; Yuling Fan; Lipeng Du; Zhigang Mei; Yang Fu
Journal:  Front Pharmacol       Date:  2021-06-11       Impact factor: 5.810

9.  Identified the Synergistic Mechanism of Drynariae Rhizoma for Treating Fracture Based on Network Pharmacology.

Authors:  Haixiong Lin; Xiaotong Wang; Ligang Wang; Hang Dong; Peizhen Huang; Qunbin Cai; Yingjie Mo; Feng Huang; Ziwei Jiang
Journal:  Evid Based Complement Alternat Med       Date:  2019-10-20       Impact factor: 2.629

10.  Uncovering Synergistic Mechanism of Chinese Herbal Medicine in the Treatment of Atrial Fibrillation with Obstructive Sleep Apnea Hypopnea Syndrome by Network Pharmacology.

Authors:  Ting Mao; Jingchun Zhang; Yu Qiao; Bei Liu; Shan Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2019-12-23       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.